Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. Issue 1 (February 2019)
- Record Type:
- Journal Article
- Title:
- Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease. Issue 1 (February 2019)
- Main Title:
- Feeding-produced subchronic high plasma levels of uric acid improve behavioral dysfunction in 6-hydroxydopamine-induced mouse model of Parkinson's disease
- Authors:
- Nakashima, Akio
Yamauchi, Atsushi
Matsumoto, Junichi
Dohgu, Shinya
Takata, Fuyuko
Koga, Mitsuhisa
Fukae, Jiro
Tsuboi, Yoshio
Kataoka, Yasufumi - Abstract:
- Abstract : The development of Parkinson's disease (PD) involves the degeneration of dopaminergic neurons caused by oxidative stress. Accumulating clinical evidence indicates that high blood levels of uric acid (UA), an intrinsic antioxidative substance, are associated with reduced risk of PD. However, this hypothesis has not been confirmed by in-vivo experiments. The present study investigated the effects of UA on behavioral abnormalities in the development of PD. We used unilateral 6-hydroxydopamine-lesioned mice, which were fed on a diet containing 1% UA and 2.5% potassium oxonate (an uricase inhibitor) to induce hyperuricemia. A significant elevation in UA levels was found in groups that were fed a UA diet. The 6-hydroxydopamine-lesioned mice showed impaired rotarod performance and increased apomorphine-induced contralateral rotations. These behavioral abnormalities were significantly reversed by feeding a UA diet for 1 week before and 5 weeks after surgery (subchronic hyperuricemia). These behavioral improvements occurred in parallel with recovery of tyrosine hydroxylase protein levels in the lesioned striatal side. The present study with a dietary hyperuricemia mice model confirms that UA exerts a neuroprotective effect on dopaminergic neuronal loss, improving motor dysfunction and ameliorating PD development.
- Is Part Of:
- Behavioural pharmacology. Volume 30:Issue 1(2019)
- Journal:
- Behavioural pharmacology
- Issue:
- Volume 30:Issue 1(2019)
- Issue Display:
- Volume 30, Issue 1 (2019)
- Year:
- 2019
- Volume:
- 30
- Issue:
- 1
- Issue Sort Value:
- 2019-0030-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2019-02
- Subjects:
- behavioral dysfunction -- 6-hydroxydopamine -- mouse -- Parkinson's disease -- uric acid
Psychopharmacology -- Periodicals
Nervous System -- drug effects -- Periodicals
Behavior -- drug effects -- Periodicals
615.78 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00008877-000000000-00000 ↗
http://www.behaviouralpharm.com/ ↗
http://journals.lww.com/pages/default.aspx ↗
http://firstsearch.oclc.org ↗ - DOI:
- 10.1097/FBP.0000000000000413 ↗
- Languages:
- English
- ISSNs:
- 0955-8810
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 1877.630000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11578.xml